| Human immunodeficiency virus I infection
Evotaz vs Rukobia
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Evotaz vs Rukobia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRukobia has a higher rate of injection site reactions vs Evotaz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rukobia but not Evotaz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Evotaz
Rukobia
At A Glance
Oral
Once daily
HIV-1 protease inhibitor with CYP3A inhibitor
Oral
Twice daily
HIV-1 attachment inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (atazanavir 300 mg/cobicistat 150 mg) orally once daily with food.
Human immunodeficiency virus I infection 600 mg orally twice daily with or without food; swallow tablets whole, do not chew, crush, or split.
Contraindications
- Clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with strong CYP3A4 inducers
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance with narrow therapeutic indices
- Coadministration with alfuzosin
- Coadministration with ranolazine
- Coadministration with dronedarone
- Coadministration with carbamazepine, phenobarbital, phenytoin
- Coadministration with colchicine in patients with hepatic or renal impairment
- Coadministration with rifampin
- Coadministration with apalutamide, encorafenib, irinotecan, ivosidenib
- Coadministration with lurasidone, pimozide
- Coadministration with dihydroergotamine, ergotamine, methylergonovine
- Coadministration with elbasvir/grazoprevir, glecaprevir/pibrentasvir
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with drospirenone/ethinyl estradiol
- Coadministration with lomitapide, lovastatin, simvastatin
- Coadministration with nevirapine
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with indinavir
- Coadministration with triazolam, orally administered midazolam
- Previous hypersensitivity to fostemsavir or any component of RUKOBIA
- Coadministration with strong CYP3A inducers, including enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (Hypericum perforatum)
Adverse Reactions
Most common (>=5%) Jaundice, rash
Serious Cardiac conduction abnormalities, rash, effects on serum creatinine, new onset or worsening renal impairment, chronic kidney disease, nephrolithiasis, cholelithiasis, hepatotoxicity, hyperbilirubinemia
Most common (>=2%) Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance, immune reconstitution inflammatory syndrome, somnolence, vomiting
Serious Immune reconstitution inflammatory syndrome, QTc prolongation, hepatic transaminase elevations in patients with hepatitis B or C virus co-infection
Pharmacology
EVOTAZ is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that prevents viral Gag and Gag-Pol polyprotein processing, and cobicistat, a CYP3A inhibitor that increases atazanavir systemic exposure.
HIV-1 attachment inhibitor; fostemsavir is a prodrug hydrolyzed to temsavir, which binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein and selectively inhibits the interaction between the virus and cellular CD4 receptors, preventing viral attachment and subsequent entry into host cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Evotaz
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Rukobia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Evotaz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Rukobia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Evotaz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Rukobia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EvotazView full Evotaz profile
RukobiaView full Rukobia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.